15855-37-5

Basic information

• Product Name: N'-Benzyl-N,N-diethylethylenediamine
• Synonyms: N'-Benzyl-N,N-diethylethylenediamine;N~1~-benzyl-N~2~,N~2~-diethylethane-1,2-diamine
• CAS NO: 15855-37-5
• Molecular Formula: C₁₃H₂₂N₂
• Molecular Weight: 206.33
• Mol File: 15855-37-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N'-Benzyl-N,N-diethylethylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N'-Benzyl-N,N-diethylethylenediamine(15855-37-5)
• EPA Substance Registry System: N'-Benzyl-N,N-diethylethylenediamine(15855-37-5)

Safety Data

• Hazardous Substances Data: 15855-37-5(Hazardous Substances Data)

Upstream product

• 100-35-6 2-(diethylamino)ethyl chloride 
• 100-46-9 benzylamine 
• 869-24-9 2-chloro-N,N-diethylethylamine hydrochloride 
• 23956-51-6 N¹-benzylidene-N²,N²-dimethylethane-1,2-diamine 
• 100-52-7 benzaldehyde 
• 6343-54-0 N-benzylformamide 
• 100-37-8 2-(Diethylamino)ethanol 
• 100-36-7 N,N-diethylethylenediamine 
• 72336-16-4 N-<(N',N'-diethylamino)acetyl>benzylamine 
• 1749-16-2 N'-(benzylideneamino)-N,N-diethylethan-1-amine 

Downstream Products

• 122147-94-8 tetra-O-acetyl-galactaric acid bis-[benzyl-(2-diethylamino-ethyl)-amide] 
• 6325-89-9 xanthene-9-carboxylic acid-[benzyl-(2-diethylamino-ethyl)-amide]; hydrochloride 
• 96074-91-8 N'.N'-Diaethyl-N-benzyl-N-fluorenyl-⁽⁹⁾-aethylendiamin 
• 125903-37-9 N-<2-(diethylamino)ethyl>-4-fluoro-N-(phenylmethyl)benzamide 
• 195005-23-3 N-Benzyl-N-ethoxymethyl-N',N'-diethyl-ethane-1,2-diamine 
• 100-36-7 N,N-diethylethylenediamine 

Relevant articles and documents

Selective Aromatic Hydroxylation with Dioxygen and Simple Copper Imine Complexes

The formation of a bis(μ-oxido)dicopper complex with the ligand 2-(diethylaminoethyl)-6-phenylpyridine (PPN) and its subsequent hydroxylation of the pendant phenyl group (studied earlier by Holland et al., Angew. Chem. Int. Ed. 1999, 38, 1139-1142) has been reinvestigated to gain a better understanding of such systems in view of the development of new synthetic applications. To this end, we prepared a simple copper imine complex system that also affords selective o-hydroxylation of aromatic aldehydes by using dioxygen as the oxidant: Applying the ligand N′-benzylidene-N,N-diethylethylenediamine (BDED), salicylaldehyde was prepared in good yields and we show that this reaction also occurs through an intermediate bis-μ-oxido copper complex. The underlying reaction mechanism for the PPN-supported complex was studied at the BLYP-D/TZVP level of density functional theory and the results for representative stationary points along reaction paths of the BDED-supported complex reveal a closely related mechanistic scenario. The results demonstrate a new facile synthetic way to introduce OH groups into aromatic aldehydes.

QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.

Synthesis of novel succinamide derivatives having the 5,11-dihydro-6h- pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I

A series of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one derivatives containing the succinamide skeleton has been synthesized and evaluated for M1, M2 and M3 muscarinic receptor binding affinities (in vitro) and M2 and M3 muscarinic receptor antagonistic activities (in vivo). Some of them showed higher and more selective binding affinities for M2 muscarinic receptors than that of AF-DX 116. Among them, 11-[3-[N-[2-(N- benzyl-N-methylamino)ethyl]-N-ethylearbamoyl]propionyl]-5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepin-6-one (68) was found to be the most potent and selective M2 muscarinic receptor antagonist in vitro. This compound also strongly inhibited the oxotremorine-induced bradycardia after intravenous administration and showed 130-fold selectivity for M2 muscarinic receptors over M3 muscarinic receptors in vivo.